Launch of National Allergy Council and National Allergy Centre of Excellence - 31 Aug 2022

In a major step towards addressing Australia’s allergy epidemic, the Hon Ged Kearney MP, Assistant Minister for Health and Aged Care, alongside allergy experts, has launched two world-first allergy organisations at a media event on Wednesday 31 August 2022 in Melbourne, during the ASCIA 2022 Conference week. 

The new National Allergy Council and National Allergy Centre of Excellence are backed by a $26.9 million Federal Government investment, and will address recommendations from the Walking the allergy tightrope report from the Parliamentary Inquiry into allergies and anaphylaxis:

  • The National Allergy Council is a natural progression of the successful National Allergy Strategy, which will remain a partnership between the Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA). The National Allergy Council will continue to implement the National Allergy Strategy, working in collaboration with the National Allergy Centre of Excellence and other stakeholders.
  • The National Allergy Centre of Excellence is an expansion of the Centre for Food & Allergy Research (CFAR). The National Allergy Centre of Excellence will generate and synthesise the evidence-base that underpins the activities of the National Allergy Council, to ensure Australia remains at the forefront of evidence-based management of allergic disease.

These initiatives will help accelerate allergy research and clinical care, to improve the lives of five million Australians living with allergic disease and prevent anaphylaxis, including needless deaths.

For more information go to www.nationalallergystrategy.org.au

Read the Media Release here

Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond


Viatris
Sanofi
Nestle
Allergy Concepts

Platinum


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer

Gold


  • dbv technologies
  • Mondelez
  • Nurticia
Silver

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William

© 2022 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 


ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.


ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.